Type 2 diabetes associated with increased risk of colorectal cancer
the ONA take:
According to a new study published in the journal Diabetes Care, researchers from the Utrecht University Institute of Pharmaceutical Sciences in Utrecht, the Netherlands, have found that type 2 diabetes is associated with a moderately increased risk of colorectal cancer.
For the study, researchers sought to investigate the risk of colorectal cancer in patients with type 2 diabetes and to assess whether treatment stage and duration of obesity affect that risk.
They identified 2,759 patients with type 2 diabetes and colorectal cancer after a median follow-up of 4.5 years from the Clinical Practice Research Datalink. All patients were on at least one prescription drug for type 2 diabetes. Results showed that type 2 diabetes was linked with a 1.3-fold increased risk for developing colorectal cancer (HR = 1.26; 95% CI: 1.18 - 1.33).
There was no association between treatment stages and colorectal cancer risk, but patients with obesity for 4 to 8 years (HR = 1.19; 95% CI: 1.06 - 1.34) and those with obesity for more than 8 years (HR = 1.28; 95% CI: 1.11 - 1.49) had a significantly increased risk of colorectal cancer.
The findings suggest that patients with type 2 diabetes, especially those who have been obese for 4 or more years, have an increased risk for developing colorectal cancer.
Type 2 diabetes is associated with a moderately increased risk of colorectal cancer.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|